Under the motto “25 Years of Progress for People with Breast Cancer,” the anniversary edition of the BIG Newsletter “Research in Focus” (Issue 21, November 2024) highlights the latest ABCSG projects and our innovative approaches to personalized breast cancer treatment.<\/p>\n
\u201cThe growing precision of breast cancer treatment, guided by biomarkers and molecular profiles, allows us to better tailor therapies to each patient\u2019s individual tumor biology and, in certain subpopulations, to avoid chemotherapy and its associated side effects. De-escalation strategies, such as focusing on endocrine therapy when appropriate, are crucial to reducing treatment burden while maintaining excellent outcomes,<\/em>\u201d emphasizes ABCSG President Professor Michael Gnant.<\/p>\n ABCSG 61 \/ TEODOR (Neoadjuvant T<\/strong>rE<\/strong>atment O<\/strong>ptimization driven by ctD<\/strong>NA and endO<\/strong>crine R<\/strong>esponsiveness), involving 256 patients across 15 sites in Austria, aims to improve personalized treatment strategies for women with early-stage breast cancer.<\/p>\n Similarly, ABCSG 63 \/ ERIKA (E<\/strong>lacestrant and RI<\/strong>bociclib in K<\/strong>i67-tested endocrine responsive breA<\/strong>st cancer) focuses on optimizing therapy. \u201cWith increasing access to a wide range of potent agents, such as oral SERDs, in the early breast cancer setting, one of our key tasks is to test these against current standards while determining who will benefit most from these novel drugs,<\/em>\u201d says study PI and ABCSG Vice President Professor Christian Singer. With 18 sites planned across Austria and Germany, ABCSG 63 \/ ERIKA will enroll 120 patients, with the first randomizations scheduled for early 2025.<\/p>\n